The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Novel combination in MM: BCMA CAR T-cells with a gamma secretase inhibitor
Andrew Cowan, MD, University of Washington, Seattle, WA, discusses a phase I first-in-human trial (NCT03502577) combining CAR T-cells expressing a fully human BCMA single-chain variable fragment with an orally administered gamma secretase inhibitor (JSMD194). Although BCMA CAR T-cell therapy has demonstrated efficacy in multiple myeloma (MM), a considerable proportion of patients relapse. Dr Cowan explains that gamma secretase inhibitors increase BCMA surface density, decrease soluble BCMA levels and enhance anti-tumor efficacy of BCMA CAR T-cells. Additionally, Dr Cowan discusses the encouraging results that demonstrate this combination therapy leads to quick responses including in patients that have failed prior BCMA targeted therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
